Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Genetically proxied inhibition of cholesterol-lowering drug targets and survival in HPV-positive and non-HPV driven head and neck cancer: a multicentre MR study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Cohort Profile: The Ontario Birth Study (OBS).

International journal of epidemiology·2026
Same author

Preconception mental health (Healthy Life Trajectories Initiative): Identifying factors associated with probable anxiety and depression among young women living in urban-poor South Africa.

PLOS mental health·2026
Same author

Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus.

medRxiv : the preprint server for health sciences·2026
Same author

Formal Statistical Replication Analysis in Lung Cancer Genome-Wide Association Studies.

medRxiv : the preprint server for health sciences·2025
Same author

Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites.

Nature communications·2025

Related Experiment Video

Updated: Sep 28, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K

Biomarker-Based Lung Cancer Screening Eligibility: Implementation Considerations.

Rayjean J Hung1,2

  • 1Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Ontario, Canada.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|April 4, 2022
PubMed
Summary

Biomarker advancements offer new lung cancer risk stratification methods. Implementing these for low-dose CT (LDCT) screening eligibility requires careful consideration and strategic planning.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells
08:54

Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells

Published on: May 20, 2020

9.3K

Related Experiment Videos

Last Updated: Sep 28, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells
08:54

Pathological Analysis of Lung Metastasis Following Lateral Tail-Vein Injection of Tumor Cells

Published on: May 20, 2020

9.3K

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Medical Imaging

Background:

  • Lung cancer screening eligibility criteria need enhancement.
  • Biomarkers show promise for lung cancer risk stratification.
  • Low-dose CT (LDCT) screening requires improved patient selection.

Discussion:

  • Implementing biomarker-based eligibility for LDCT screening presents challenges.
  • Key considerations include biomarker validation and integration into clinical practice.
  • Mitigation strategies are essential for successful biomarker implementation.

Key Insights:

  • Biomarkers can refine lung cancer risk assessment.
  • Successful implementation hinges on addressing practical and logistical hurdles.
  • A strategic approach is needed for biomarker-guided screening.

Outlook:

  • Future screening protocols may incorporate biomarker data.
  • Further research is needed to optimize biomarker assays and interpretation.
  • Biomarker integration could improve LDCT screening efficacy and efficiency.